急性早幼粒细胞白血病（APGL）是以白血病细胞分化阻滞在原始和早幼粒细胞阶段为特点的急性白血病。体外实验及临床应用已经证明维甲酸（RA）可以诱导 APGL 的白血病细胞向粒系方向分化成熟。近几年国内外均有应用 RA 治疗 APGL获得完...急性早幼粒细胞白血病（APGL）是以白血病细胞分化阻滞在原始和早幼粒细胞阶段为特点的急性白血病。体外实验及临床应用已经证明维甲酸（RA）可以诱导 APGL 的白血病细胞向粒系方向分化成熟。近几年国内外均有应用 RA 治疗 APGL获得完全缓解（CR）的报道.我院从1987年12月开始,应用 RA 治疗急性早幼粒细胞白血病（M<sub>3</sub>）4例。兹报告如下。展开更多
Objective.:To determine the ability of patients to be treated with biweekly bevacizumab and weekly taxane chemotherapy in women with advanced,refractory ovarian cancer. Methods.:Ten patients with advanced,recurrent,an...Objective.:To determine the ability of patients to be treated with biweekly bevacizumab and weekly taxane chemotherapy in women with advanced,refractory ovarian cancer. Methods.:Ten patients with advanced,recurrent,and refractory ovarian cancer who were treated with biweekly bevacizumab (10 mg/kg) and weekly taxane (paclitaxel or docetaxel) chemotherapy days 1,8,15,and 22 every 28 days were identified retrospectively. All patients were followed with serial CA125 measurements prior to each cycle of therapy; cross-sectional imaging was not used to follow response to therapy. Toxicities were assessed prior to each cycle of treatment. Results.:Of the 10 patients treated with weekly taxane and biweekly bevacizumab therapy,all 9 that were evaluable had a decrease in CA125. Five patients have had an increase in CA125 after therapy after a median of three cycles (range 1-4),while 3 patients experienced normalization of CA125 and another with continued improvement in CA125. All symptomatic patients experienced rapid palliation of pain,nausea,and ascites. Side effects have been mild,with no grade 3 or 4 toxicities noted. No treatment delays or discontinuations have been necessary. Conclusion.:Treatment of advanced,recurrent,refractory epithelial ovarian cancer with bevacizumab and weekly taxane chemotherapy leads to significant,albeit temporary,improvement in the cancer-related symptoms in women treated on this regimen,and short-term exposure to these agents is not associated with significant toxicity. Thus,continued investigation of bevacizumab with weekly scheduling of cytotoxic chemo- therapy is imperative.展开更多
In the past 15 years, we have seen few therapeutic advances for patients with pancreatic cancer, which is the fourth leading cause of cancer-related death in the United States. Currently, only about 6% of patients wit...In the past 15 years, we have seen few therapeutic advances for patients with pancreatic cancer, which is the fourth leading cause of cancer-related death in the United States. Currently, only about 6% of patients with advanced disease respond to standard gemcitabine therapy, and median survival is only about 6 mo. Moreover, phase Ⅲ trials have shown that adding various cytotoxic and targeted chemotherapeutic agents to gemcitabine has failed to improve overall survival, except in cases in which gemcitabine combined with erlotinib show minimal survival benefi t. Several metaanalyses have shown that the combination of gemcitabine with either a platinum analog or capecitabine may lead to clinically relevant survival prolongation, especially for patients with good performance status. Meanwhile, many studies have focused on the pharmacokinetic modulation of gemcitabine by fi xed-dose administration, and metabolic or transport enzymes related to the response and toxicity of gemcitabine. Strikingly, a phase Ⅲ trial in 2010 showed that, in comparison to gemcitabine alone, the FOLFIRINOX regimen in patients with advanced disease and good performance status, produced better median overall survival, median progression-free survival, and objective response rates. This regimen also resulted in greater, albeit manageable toxicity.展开更多
文摘急性早幼粒细胞白血病（APGL）是以白血病细胞分化阻滞在原始和早幼粒细胞阶段为特点的急性白血病。体外实验及临床应用已经证明维甲酸（RA）可以诱导 APGL 的白血病细胞向粒系方向分化成熟。近几年国内外均有应用 RA 治疗 APGL获得完全缓解（CR）的报道.我院从1987年12月开始,应用 RA 治疗急性早幼粒细胞白血病（M<sub>3</sub>）4例。兹报告如下。
文摘Objective.:To determine the ability of patients to be treated with biweekly bevacizumab and weekly taxane chemotherapy in women with advanced,refractory ovarian cancer. Methods.:Ten patients with advanced,recurrent,and refractory ovarian cancer who were treated with biweekly bevacizumab (10 mg/kg) and weekly taxane (paclitaxel or docetaxel) chemotherapy days 1,8,15,and 22 every 28 days were identified retrospectively. All patients were followed with serial CA125 measurements prior to each cycle of therapy; cross-sectional imaging was not used to follow response to therapy. Toxicities were assessed prior to each cycle of treatment. Results.:Of the 10 patients treated with weekly taxane and biweekly bevacizumab therapy,all 9 that were evaluable had a decrease in CA125. Five patients have had an increase in CA125 after therapy after a median of three cycles (range 1-4),while 3 patients experienced normalization of CA125 and another with continued improvement in CA125. All symptomatic patients experienced rapid palliation of pain,nausea,and ascites. Side effects have been mild,with no grade 3 or 4 toxicities noted. No treatment delays or discontinuations have been necessary. Conclusion.:Treatment of advanced,recurrent,refractory epithelial ovarian cancer with bevacizumab and weekly taxane chemotherapy leads to significant,albeit temporary,improvement in the cancer-related symptoms in women treated on this regimen,and short-term exposure to these agents is not associated with significant toxicity. Thus,continued investigation of bevacizumab with weekly scheduling of cytotoxic chemo- therapy is imperative.
文摘In the past 15 years, we have seen few therapeutic advances for patients with pancreatic cancer, which is the fourth leading cause of cancer-related death in the United States. Currently, only about 6% of patients with advanced disease respond to standard gemcitabine therapy, and median survival is only about 6 mo. Moreover, phase Ⅲ trials have shown that adding various cytotoxic and targeted chemotherapeutic agents to gemcitabine has failed to improve overall survival, except in cases in which gemcitabine combined with erlotinib show minimal survival benefi t. Several metaanalyses have shown that the combination of gemcitabine with either a platinum analog or capecitabine may lead to clinically relevant survival prolongation, especially for patients with good performance status. Meanwhile, many studies have focused on the pharmacokinetic modulation of gemcitabine by fi xed-dose administration, and metabolic or transport enzymes related to the response and toxicity of gemcitabine. Strikingly, a phase Ⅲ trial in 2010 showed that, in comparison to gemcitabine alone, the FOLFIRINOX regimen in patients with advanced disease and good performance status, produced better median overall survival, median progression-free survival, and objective response rates. This regimen also resulted in greater, albeit manageable toxicity.
